Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose colchicine for secondary prevention of cardiovascular disease
2015-005568-40Phase 3Completed
- Sponsor
- WCCN
- Start
- Apr 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis and cardiac morbidity comparing Colchicine with Placebo (2 arms). Primary endpoint: First occurrence of major adverse cardiovascular event composite. Started Apr 2016; status: completed.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosiscardiac morbidity
Beyond the preview
Go deeper on 2015-005568-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005568-40.